In animal models of non-alcoholic steatohepatitis (NASH), SAR mitigated hepatic steatosis and fibrosis via a modulatory effect on inflammatory cytokines and adiponectin levels. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.